NFE2L2 and breast carcinoma: In addition, the genetic variants in NFE2L2, NAD(P)H quinone dehydrogenase 1 (NQO1), nitric oxide synthase 3 (NOS3), and heme oxygenase 1 (HMOX-1), exhibit lower ROS detoxification capabilities—although they are not associated with a breast cancer risk individually—in postmenopausal women with three or more of such modifications, increasing the risk of breast cancer, especially when combined with a high iron intake [52].